NEW YORK (GenomeWeb News) – Liverpool, UK-based Biofortuna announced today that it has extended an exclusive distribution agreement with Abbott.

Under the new agreement, Abbott will distribute Biofortuna's SSPGo range of freeze dried HLA typing kits in France, Spain, Portugal, and the Benelux countries. With this new agreement, Abbott now has exclusive rights to distribute the kits, along with the Verdict interpretation software, in all global territories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.